Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients

Clinical Pharmacokinetics

Volumn 45, Issue 5, 2006, Pages 493-501

  Simon, Nicolas ^a,b,e   Dussol, Bertrand ^c   Sampol, Emmanuelle ^a   Purgus, Raj ^c   Brunet, Philippe ^c   Lacarelle, Bruno ^a   Berland, Yvon ^c   Bruguerolle, Bernard ^a,b   Urien, Saïk ^d  

^a TIMONE HOSPITAL   (France)

^b Laboratory of Medical and Clinical Pharmacology   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CEFTRIAXONE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BRONCHOPNEUMONIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MALE; MINIMUM INHIBITORY CONCENTRATION; OPEN STUDY; OUTPATIENT; PARAMETER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIMULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BRONCHOPNEUMONIA; CEFTRIAXONE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 33646134844     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645050-00004     Document Type: Article

References (20)

1. Lamb HM, Ormrod D, Scott LJ, et al. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs 2002; 62: 1041-89
2. Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest 2001; 120: 1883-7
3. Fridkin SK. Vancomycin-intermediate and resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001; 32: 108-15
4. Perry TR, Schentag JJ. Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding. Clin Pharmacokinet 2001; 40: 685-94
5. Chiu LM, Menhinick AM, Johnson PW, et al. Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers. J Antimicrob Chemother 2002; 50: 1075-9
6. Gabutti L, Taminelli-Beltraminelli C, Marone C. Clearance of ceftriaxone during haemodialysis using cuprophane, haemophane and polysulfone dialysers. Eur J Clin Pharmacol 1997; 53: 123-6
7. Patel IH, Sugihara JG, Weinfeld RE, et al. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob Agents Chemother 1984; 25: 438-42
8. Al-Rawithi S, Hussein R, Raines DA, et al. Sensitive assay for the determination of cefazolin or ceftriaxone in plasma utilizing LC. J Pharm Biomed Anal 2000; 22: 281-6
9. Boeckmann A, Scheiner L, Beal S. NONMEM Users guide: part V. San Francisco (CA): University of California, 1994
10. Karlsson MO, Jonsson EN, Wiltse CG, et al. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm 1998; 26: 207-46
11. Ette E. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997; 37: 486-95
12. Parke J, Holford N, Charles B. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999; 59: 19-29
13. MacNamara PJ, Trueb V, Stoeckel K. Protein binding of ceftriaxone in extravascular fluids. J Pharm Sci 1988; 77: 401-4
14. Coffey JJ, Bullock FJ, Schoenemann PT. Numerical solution of nonlinear pharmacokinetic equations: effects of plasma protein binding on drug distribution and elimination. J Pharm Sci 1971; 60: 1623-8
15. Ihara R, Gentleman R. R: a language for data analysis and graphics. J Computational and Graphical Statistics 1996; 5: 299-341
16. Joynt GM, Lipman J, Gomersall CD, et al. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001; 47: 421-9
17. Hayton WL, Stoeckel K. Age-associated changes in ceftriaxone pharmacokinetics. Clin Pharmacokinet 1986; 11: 76-86
18. Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet 1995; 28: 143-60
19. Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-46
20. Pallares R, Fenoll A, Linares J, et al. The epidemiology of antibiotic resistance in Streptococcus pneumoniae and the clinical relevance of resistance to cephalosporins, macrolides and quinolones. Int J Antimicrob Agents 2003; 22: S15-24